Targeted Medical Pharma, Inc. (OTCMKTS:TRGM – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.00 and ...
Regulatory ApprovalFormycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 08.01.2025 / 14:30 CET/CESTThe issuer is solely ...